2m 2m 2m 2m 2m 2m 2m
PRELUDE THERAP (PRLD)
NASDAQ
$3.66$0.00 (0.00%)
Price as of Jun 03, 2026 7:01 PM EDT- $254.5MMarket Cap
- 274.21%1-Year Change
- BiotechnologyIndustry
PRELUDE THERAP (PRLD)
$3.66$0.00 (0.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 12.1M +73.43% | 7.0M N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 12.1M +73.43% | 7.0M N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -94.3M -20.08% | -118.0M +14.12% | -103.4M +11.31% | -92.9M +7.04% | |
Depreciation and Amortization Expense | 1.7M -3.44% | 1.8M +51.58% | 1.2M -11.71% | 1.3M +44.70% | |
Total Operating Expenses | 116.7M -20.45% | 146.7M +10.91% | 132.3M +7.07% | 123.5M +8.62% | |
Operating Profit | -104.6M -25.16% | -139.7M +5.62% | -132.3M +7.07% | -123.5M +8.62% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 5.1M -59.59% | 12.5M +20.07% | 10.4M +28.92% | 8.1M +296.96% | |
Income before Taxes | -104.6M -25.16% | -139.7M +5.62% | -132.3M +7.07% | -123.5M +8.62% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -99.5M -21.76% | -127.2M +4.38% | -121.8M +5.54% | -115.4M +3.35% | |
Net Income from Continuing Operations Applicable to Common | -99.5M -21.76% | -127.2M +4.38% | -121.8M +5.54% | -115.4M +3.35% | |
Basic EPS and Net Income | -1.29 -23.21% | -1.68 -16.83% | -2.02 -17.21% | -2.44 +0.41% | |
Diluted EPS and Net Income | -1.29 -23.21% | -1.68 -16.83% | -2.02 -17.21% | -2.44 +0.41% | |
Basic Weighted Average Shares | 77.0M +1.52% | 75.8M +25.60% | 60.4M +27.41% | 47.4M +2.87% | |
Diluted Weighted Average Shares | 77.0M +1.52% | 75.8M +25.60% | 60.4M +27.41% | 47.4M +2.87% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 35.3M +182.64% | 12.5M -50.68% | 25.3M -17.36% | 30.6M -3.84% | |
Short-Term Investments | 68.0M -43.90% | 121.1M -41.66% | 207.6M +21.34% | 171.1M -34.03% | |
Cash and Cash Equivalents and Short-Term Investments | 103.2M -22.75% | 133.6M -42.64% | 232.9M +15.47% | 201.7M -30.73% | |
Total Current Assets | 105.7M -22.23% | 135.9M -42.32% | 235.6M +15.27% | 204.4M -30.75% | |
Accumulated Depreciation | 6.9M +31.78% | 5.3M +47.45% | 3.6M +7.44% | 3.3M +66.12% | |
Property and Plant and Equipment and Net | 5.1M -24.44% | 6.8M -7.62% | 7.3M +49.25% | 4.9M +24.92% | |
Total Long-Term Assets | 5.1M -24.44% | 6.8M -7.62% | 7.3M +36.25% | 5.4M +1,674.26% | |
Total Assets | 141.3M -19.49% | 175.5M -36.79% | 277.7M +25.93% | 220.5M -27.73% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 53.0M +106.68% | 25.6M +17.46% | 21.8M +0.59% | 21.7M +13.03% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 2.8M -8.06% | 3.1M -7.46% | 3.3M -0.65% | 3.4M +10,403.13% | |
Total Liabilities | 72.7M +64.97% | 44.1M +8.58% | 40.6M +61.89% | 25.1M +30.53% | |
Retained Earnings | -683.1M +17.05% | -583.6M +27.86% | -456.4M +36.42% | -334.6M +52.68% | |
Total Stockholders Equity | 68.6M -47.79% | 131.5M -44.55% | 237.1M +21.31% | 195.4M -31.64% | |
Total Shares Outstanding | 48.2M -12.55% | 55.1M +0.43% | 54.9M +14.65% | 47.9M +0.62% | |
Cash Flow | |||||
Cash from Operating Activities | -56.3M -45.28% | -102.9M -3.90% | -107.1M +27.87% | -83.7M +0.24% | |
Capital Expenditures | 67,000 -91.23% | 764,000 -78.25% | 3.5M +16.36% | 3.0M +29.96% | |
Cash from Investing Activities | 53.5M -40.73% | 90.2M +360.32% | -34.6M -142.41% | 81.7M +130.97% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 24.8M +20,780.00% | -120,000 -100.09% | 136.4M +16,635.58% | 815,000 -99.51% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -861.33% -56.85% | -1,995.91% N/A | N/A N/A | N/A N/A | |
Return on Assets | -62.81% +11.91% | -56.12% +14.75% | -48.91% +11.35% | -43.93% +3.96% | |
Return on Equity | -99.45% +44.10% | -69.01% +22.50% | -56.33% +17.45% | -47.97% +6.95% | |
Revenue Growth | 73.43% N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 1.99 -62.37% | 5.30 -50.89% | 10.79 +14.60% | 9.42 -38.73% | |
Cash Ratio | 0.67 +36.75% | 0.49 -58.01% | 1.16 -17.84% | 1.41 -14.93% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow